BAP1 and intrahepatic cholangiocarcinoma: Surprisingly, a recent case report demonstrated that a patient with metastatic intrahepatic cholangiocarcinoma carrying a BRCA1-associated protein 1 (BAP1) mutation and RAD21 amplification benefited from PARP inhibitor treatment (36).